ARROWHEAD PHARMACEUTICALS, INC. Cash and Restricted Cash
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Cash and Restricted Cash of $54.76 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $54.76M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $188.52M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $201.64M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $226.55M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $54.76M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $188.52M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $201.64M 10-Q · filed 2026-02-05 |
| 2025-09-30 | $226.55M 10-Q · filed 2026-08-04 |
| 2025-06-30 | $129.79M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $185.71M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $53.89M 10-Q · filed 2026-02-05 |
| 2024-09-30 | $102.69M 10-Q · filed 2026-08-04 |
| 2024-06-30 | $69.40M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $127.70M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $58.22M 10-Q · filed 2025-02-10 |
| 2023-09-30 | $110.89M 10-K · filed 2025-11-25 |
| 2023-06-30 | $105.33M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $134.96M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $202.25M 10-Q · filed 2024-02-06 |
| 2022-09-30 | $108.00M 10-K · filed 2025-11-25 |
| 2021-09-30 | $184.43M 10-K · filed 2024-11-26 |
| 2020-09-30 | $143.58M 10-K · filed 2023-11-29 |
| 2019-09-30 | $221.80M 10-K · filed 2022-11-28 |
| 2019-06-30 | $189.33M 10-Q · filed 2019-08-05 |
| 2018-09-30 | $30.13M 10-Q · filed 2019-08-05 |
| 2018-06-30 | $28.00M 10-Q · filed 2019-08-05 |
| 2017-09-30 | $24.84M 10-Q · filed 2019-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |